Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

population health screening

- PMLiVE

MaxCyte gets green light for solid tumour cell therapy

Its first CAR therapy will be tested in patients with ovarian cancer

- PMLiVE

‘Common Rulebook’ Brexit plans include medicines – but face backlash

Government compromises could be opposed from both sides

- PMLiVE

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare

- PMLiVE

Novartis rejects claims it misled Senate over Cohen links

Report says Novartis discussed drug-pricing with the President’s former ‘fixer’

- PMLiVE

May’s Brexit plan cautiously welcomed by biopharma sector

The white paper says the UK should adhere to EMA regulations post-Brexit

- PMLiVE

Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks ‘soft Brexit’ plan

The latest from pharma, biotech and healthcare

- PMLiVE

GSK sells eczema and psoriasis drug to Dermavant for £250m

The British group is selling off assets outside core therapy areas to boost R&D

- PMLiVE

Fishawack acquires brand communications agency Healthcircle

The agency will work alongside Fishawack’s medical communication businesses

- PMLiVE

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

The latest from pharma, biotech and healthcare

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

- PMLiVE

Pfizer builds gap between pharma and consumer health units

Its consumer health division will become a standalone unit after lack of buyer interest

- PMLiVE

The Pharma UK Twitter Ranking 2018 [RESEARCH]

The second edition in our Pharma Social Media Series, the UK Twitter Ranking.

An agency called Owen

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links